Salkind Gene made five open market purchases of UPEXI, INC. ($UPXI) shares over the last year, totaling $1.32 million, with the most recent on November 20, 2025. These buys rank 414th among nearly 5,000 insiders, above the average of $1.46 million per buyer and 3.3 transactions. Salkind Gene reported no open market sales in the period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 11, 2026 | Coeptis Therapeutics Holdings, Inc. | $COEP | Salkind Gene | Director | A | Common Stock | 3250 | $0.00 | 13,161.0000 | 4,745,089 | 32.79% | 0.07% |
| Feb. 11, 2026 | Coeptis Therapeutics Holdings, Inc. | $COEP | Salkind Gene | Director | M | Common stock | 5700 | $10.56 | 13,161.0000 | 4,745,089 | 76.40% | 0.12% |
| Dec. 31, 2025 | Mobiquity Technologies, Inc. | $MOBQ | Salkind Gene | Director | A | Common Stock Options | 250000 | $0.00 | 761,544.0000 | 22,867,746 | 48.87% | 1.09% |
| Nov. 20, 2025 | UPEXI, INC. | $UPXI | Salkind Gene | Not found | P | Common Stock | 50000 | $2.55 | 218,750.0000 | 58,893,261 | 29.63% | 0.08% |
| Nov. 17, 2025 | UPEXI, INC. | $UPXI | Salkind Gene | Not found | P | Common Stock | 100000 | $2.65 | 738,220.0000 | 58,893,261 | 15.67% | 0.17% |
| Nov. 17, 2025 | UPEXI, INC. | $UPXI | Salkind Gene | Not found | P | Common Stock | 100000 | $2.81 | 738,220.0000 | 58,893,261 | 15.67% | 0.17% |
| Sept. 15, 2025 | Mobiquity Technologies, Inc. | $MOBQ | Salkind Gene | Director | A | Common Stock | 25000 | $1.00 | 8,668,695.0000 | 20,010,909 | 0.29% | 0.12% |
| Sept. 15, 2025 | Mobiquity Technologies, Inc. | $MOBQ | Salkind Gene | Director | A | Convertible notes | 100000 | $0.00 | 511,544.0000 | 20,010,909 | 24.30% | 0.50% |
| July 16, 2025 | UPEXI, INC. | $UPXI | Salkind Gene | Not found | A | Common Stock | 50000 | $0.00 | 435,370.0000 | 38,270,571 | 12.97% | 0.13% |
| July 16, 2025 | UPEXI, INC. | $UPXI | Salkind Gene | Not found | A | Common Stock | 150000 | $0.00 | 585,370.0000 | 38,270,571 | 34.45% | 0.39% |
| July 11, 2025 | UPEXI, INC. | $UPXI | Salkind Gene | Not found | P | Common Stock | 20243 | $4.94 | 385,370.0000 | 38,270,571 | 5.54% | 0.05% |
| Jan. 17, 2025 | UPEXI, INC. | $UPXI | Salkind Gene | Not found | A | Options to buy common stock | 25000 | $0.00 | 25,000.0000 | 1,045,429 | 9999.99% | 2.39% |
| April 17, 2025 | UPEXI, INC. | $UPXI | Salkind Gene | Not found | P | Common Stock | 241229 | $2.28 | 365,127.0000 | 1,045,429 | 194.70% | 23.08% |
| April 17, 2025 | UPEXI, INC. | $UPXI | Salkind Gene | Not found | A | Options to buy common stock | 35000 | $0.00 | 35,000.0000 | 1,045,429 | 9999.99% | 3.35% |
| March 4, 2025 | Coeptis Therapeutics Holdings, Inc. | $COEP | Salkind Gene | Director | A | Non-qualified Stock Options (right to buy) | 5700 | $0.00 | 8,950.0000 | 1,924,639 | 175.38% | 0.30% |
| Dec. 30, 2024 | Mobiquity Technologies, Inc. | $MOBQ | Salkind Gene | Director | X | Convertible notes | 210000 | $0.00 | 411,544.0000 | 0 | 33.79% | 0.00% |
| Dec. 30, 2024 | Mobiquity Technologies, Inc. | $MOBQ | Salkind Gene | Director | X | Common Stock | 420000 | $0.50 | 8,643,695.0000 | 0 | 5.11% | 0.00% |
| Oct. 8, 2024 | Mobiquity Technologies, Inc. | $MOBQ | Salkind Gene | Director | A | Common Stock Options | 250000 | $0.00 | 831,544.0000 | 0 | 42.99% | 0.00% |
| Aug. 6, 2024 | Mobiquity Technologies, Inc. | $MOBQ | Salkind Gene | Director | C | Series H Preferred Stock | 751973 | $0.00 | 581,544.0000 | 0 | 56.39% | 0.00% |
| Aug. 6, 2024 | Mobiquity Technologies, Inc. | $MOBQ | Salkind Gene | Director | C | Common Stock | 7675160 | $0.20 | 8,223,695.0000 | 0 | 1399.21% | 0.00% |
| Aug. 6, 2024 | Mobiquity Technologies, Inc. | $MOBQ | Salkind Gene | Director | C | Series H Preferred Stock | 751973 | $0.00 | 616,201.0000 | 0 | 54.96% | 0.00% |
| Aug. 6, 2024 | Mobiquity Technologies, Inc. | $MOBQ | Salkind Gene | Director | C | Common Stock | 7675160 | $0.20 | 8,223,695.0000 | 0 | 1399.21% | 0.00% |
| July 25, 2024 | Mobiquity Technologies, Inc. | $MOBQ | Salkind Gene | Director | A | Convertible Promissory Notes | 50000 | $0.00 | 8,135,931.0000 | 0 | 0.62% | 0.00% |
| June 27, 2024 | Mobiquity Technologies, Inc. | $MOBQ | Salkind Gene | Director | A | Convertible Promissory Notes | 160000 | $0.00 | 8,035,931.0000 | 0 | 2.03% | 0.00% |
| Jan. 5, 2024 | Coeptis Therapeutics Holdings, Inc. | $COEP | Salkind Gene | Director | P | Common Stock | 11600 | $0.69 | 316,740.0000 | 1,284,499 | 3.80% | 0.90% |
| Aug. 25, 2023 | Coeptis Therapeutics Holdings, Inc. | $COEP | Salkind Gene | Director | P | Common Stock | 28638 | $0.91 | 278,684.0000 | 0 | 11.45% | 0.00% |
| Aug. 29, 2023 | Coeptis Therapeutics Holdings, Inc. | $COEP | Salkind Gene | Director | P | Common Stock | 4006 | $1.01 | 254,092.0000 | 0 | 1.60% | 0.00% |
| Jan. 27, 2023 | Coeptis Therapeutics Holdings, Inc. | $COEP | Salkind Gene | Director | A | Non-qualified Stock Options (right to buy) | 30000 | $0.00 | 30,000.0000 | 0 | 9999.99% | 0.00% |